Implications of Post-LLETZ “Treatment Failure” for Further Management of HIV-Infected Women

Table 1

Comparative clinico-pathologic data: HIV-infected versus uninfected.

Variables	HIV-infected; 𝑁=120	HIV-uninfected; 𝑁=139	𝑡	𝑃
Age (years)	39.5 ± 6.5 [39.0]; (22.0–58.0)*	46.3±10.9  [45.0]; (25.0–77.0)	6.0	<0.0001
Weeks between LLETZ and hysterectomy	28.0 (2–96)**	18.0 (3–64)		0.0016
𝑁 reported positive margins	94 (78.3)***	128 (92.1)		0.03
CIN1 on hysterectomy or repeat LLETZ	5 (4.2)	8 (5.7)		0.18
CIN2+	106 (88.3)	121 (87.1)		0.28
Microinvasive cancer	9 (7.5)	10 (7.2)		0.06
Regression to ≤CIN1	20 (16.7)	39 (28.1)		0.035
Progression to ≥CIN2+	24 (20.0)	3 (2.1)		0.027
Persistence	76 (63.3)	97 (69.8)		0.10

∗Values are mean ± SD [Median]; ∗∗Values are median (range); ∗∗∗Values are numbers (%).